Hemoperfusion in 1981.
The present status of hemoperfusion using the principle of artificial cells is described in detail using coated charcoal hemoperfusion as an example. The laboratory and clinical results show that in 1981 increasing numbers of new commercial models are approaching the efficiency and blood compatibility of the ACAC laboratory system. The results of hemoperfusion for uremia, acute intoxication and hepatic coma are analyzed. Other approaches are briefly discussed.
D000418:Albumins / Q000627:therapeutic use; D000818:Animals; D000837:Anion Exchange Resins / Q000627:therapeutic use; D002606:Charcoal / Q000627:therapeutic use*; D002675:Child, Preschool; D003101:Collodion / Q000627:therapeutic use; D004800:Enzymes, Immobilized / Q000627:therapeutic use; D006464:Hemoperfusion / Q000009:adverse effects / Q000639:trends*; D006501:Hepatic Encephalopathy / Q000188:drug therapy / Q000401:mortality / Q000628:therapy; D006801:Humans; D007164:Immunosorbents / Q000627:therapeutic use; D007223:Infant; D007676:Kidney Failure, Chronic / Q000188:drug therapy / Q000628:therapy; D010539:Permeability; D011041:Poisoning / Q000188:drug therapy / Q000401:mortality / Q000628:therapy; D051381:Rats; D011919:Rats, Inbred Strains; D006435:Renal Dialysis; D014462:Ultrafiltration / Q000295:instrumentation; D014511:Uremia / Q000188:drug therapy* / Q000628:therapy
D000418:Albumins; D000837:Anion Exchange Resins; D004800:Enzymes, Immobilized; D007164:Immunosorbents; D002606:Charcoal; D003101:Collodion